Home › Funds › Rhenman & Partners Asset Management AB › VRTX

Rhenman & Partners Asset Management AB position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Rhenman & Partners Asset Management AB reported holding 48,935 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$25.6M, representing 2.83% of its reported portfolio and ranking #6 among its reported holdings. Rhenman & Partners Asset Management AB has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)48.94K sh
Reported value held$25.58M
Portfolio Weight2.83%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Rhenman & Partners Asset Management AB's VRTX position evolved

Rhenman & Partners Asset Management AB first disclosed a stake in VRTX in Q3 2023 at 76,500 shares (US$26.6M). The position peaked in Q4 2023 at 95,000 shares, worth US$38.7M. Across 13 filings, Rhenman & Partners Asset Management AB increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 48,935 shares valued at US$25.6M — an increase of 18,250 shares quarter over quarter.. Notable position changes include a 41% trim in Q1 2024 (shares rose 12% over the following quarter), a 34% increase in Q1 2025 (shares fell 8% over the following quarter), a 59% increase in Q3 2026 (shares rose 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 76.50K $26.60M New
Q4 2023 95.00K $38.65M Add
Q1 2024 56.50K $23.62M Reduce
Q2 2024 54.00K $25.31M Reduce
Q3 2024 47.75K $22.21M Reduce
Q4 2024 50.00K $20.14M Add
Q1 2025 66.75K $32.36M Add
Q2 2025 61.45K $27.36M Reduce
Q3 2025 46.95K $18.39M Reduce
Q4 2025 34.26K $15.53M Reduce
Q1 2026 43.48K $19.42M Add
Q2 2026 30.68K $15.24M Reduce
Q3 2026 48.94K $25.58M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Rhenman & Partners Asset Management AB held VRTX?

Rhenman & Partners Asset Management AB has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Rhenman & Partners Asset Management AB's current position in VRTX?

As of Q3 2026, Rhenman & Partners Asset Management AB holds 48.94K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $25.58M, representing 2.83% of its reported portfolio and ranking #6.

Has Rhenman & Partners Asset Management AB been buying or selling VRTX?

In the latest 13F filing (Q3 2026), Rhenman & Partners Asset Management AB increased its position in VRTX. The position peaked in Q4 2023 at 95.00K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.